The concern of generic competition has repeatedly loomed over copyright’s blockbuster drug, Viagra, raising questions about the prospects of similar medicinal investments. While early years saw impressive gains, the intellectual property lapse has created the door for less expensive substitutes, likely reducing profitability and creating a genuin